Skip to main content
Premium Trial:

Request an Annual Quote

NuSep to Buy BioInquire

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian bioseparations company NuSep has signed an agreement to buy proteomics software maker BioInquire through a cash, stock, and milestone arrangement worth an expected $3 million or more.

BioInquire, based in Athens, Ga., sells the ProteoIQ software for analysis and identification of protein samples post-processing on a mass spec instrument against large structure and function databases.

NuSep said that its customers can use the ProteoIQ software to identify proteins they separated with its ProteomeSep MF10 instruments.

NuSep offers precast gels, separation instruments, including the ProteomeSep, biological research supplies, and the InqSep supply service for identification, cataloguing, and analysis for mass spectrometry projects.

Under the agreement, NuSep will pay three times BioInquire's 2010 calendar net profit. That includes $1.5 million when the acquisition is approved; $500,000 in NuSep shares at the end of 2010; $1 million on March 31, 2011, based on achievement of a profit milestone; and the balance of three times the BioInquire net profit for the 12 months up to March 2011.

NuSep expects the combined company to have $5.5 million in revenues for the 09/10 Fiscal Year ended June 30, 2010.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.